<DOC>
	<DOCNO>NCT01061723</DOCNO>
	<brief_summary>Primary objective : - evaluate efficacy Sarilumab patient Ankylosing Spondylitis [ AS ] use Assessment AS work group criterion [ ASAS ] 20 % response criterion [ ASAS20 ] Secondary objective : - demonstrate Sarilumab effective : - assessment high level response ( ASAS 40 % response criterion [ ASAS40 ] ) - partial remission - disease activity - range motion - Magnetic Resonance Imaging [ MRI ] spine - ass safety tolerability Sarilumab patient AS well pharmacokinetic profile Sarilumab patient AS</brief_summary>
	<brief_title>Dose Ranging Study Evaluate Efficacy Safety SAR153191 ( REGN88 ) Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description>The duration participation study patient approximately 22 week ; include 4 week screen period , 12-week double-blind treatment period 6-week safety follow-up period .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Inclusion criterion : Diagnosis AS accord New York modify criteria Patient must adequate trial least 2 different Non Steroidal AntiInflammatory Drugs [ NSAIDs ] take least 2 week case , stable dose ≥2 week intolerant NSAIDs Patient must active AS ≥3 month screen active disease must present screen baseline ; Active AS define : Bath Ankylosing Spondylitis Disease Activity Index [ BASDAI ] score ≥4 ( Numerical Rating Scale 010 ) Total back pain score ≥4 ( Numerical Rating Scale 010 ) Patients treated corticosteroid must stable dose ≥2 week prior baseline Patients treated Disease Modifying AntiRheumatic Drugs [ DMARDs ] hydroxychloroquine , sulfasalazine methotrexate ( MTX ) must stable dose ≥12 week prior baseline Exclusion criterion : &lt; 18 year old ≥75 year old Complete fusion spine Past history non response antiTumor Necrosis Factors [ TNFs ] treatment non response biological treatment AS Any past current treatment antiTNF 's biological agent within 3 month prior screen Treatment DMARDs except hydroxychloroquine , sulfasalazine MTX MTX &gt; 25 mg/week hydroxychloroquine &gt; 400 mg/day Sulfasalazine &gt; 3 g/day Treatment oral prednisone equivalent corticosteroid &gt; 10 mg/day within 6 week prior screen Use intramuscular intraarticular corticosteroid within last 4 week screen Previous treatment cyclosporine , azathioprine The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>